08 Overseas financing secured (Pre-money valuation : KRW 40 billion, USD 1 million invested by Prof. Mariel Birnbaumer, a U.S.-based expert in biotechnology and biomedical sciences)
07 Regulatory Sandbox approval for Advanced for Regenerative Medicine Therapy for recurrent glioblastoma
04 Selected for the Texas C&D Incubation Office Residency Support Program: “U.S. local incubation and business development support for CB-11, a gene and cell therapy for glioblastoma”
04 Selected for the 2026 Jeonbuk Advanced Bio Boost-Up Platform Super-Gap R&D Project: “Advancement of manufacturing and quality control (CMC) and establishment of analytical and evaluation technologies for CB-31, a gene and cell therapy based on a multi-gene co-expressing MSC platform”
03 Selected for the 2026 Biohealth Global Expansion Support Program (K-VIP): “Gene and cell therapy candidate for recurrent glioblastoma (CB-11, in preparation for U.S. FDA IND submission)”
02 Received Orphan Drug Designation (ODD) from the U.S. FDA for CB-11, a therapy for malignant brain tumors
2025
12 INNO-BIZ Certification – Ministry of SMEs and Startups
07 Head office relocated (201 Cheomdangwahak-ro, Sinjeong-dong, Jeongeup-si, Jeollabuk-do, South Korea)
06 Selected for 2025 Scale-up TIPS R&D Project: “Process optimization and regulatory strategy for CB-11, an advanced biopharmaceutical for malignant brain tumor”
05 Selected for Advanced Regenerative Medicine Clinical Study: “Clinical safety and tolerability study of MSC11FCD with suicide gene in newly diagnosed glioblastoma patients”
03 Certified as a Women-Owned Business – Ministry of SMEs and Startups
2024
12 Series B financing secured (Pre-money valuation: KRW 25.4 billion, KRW 5 billion raised from Laguna Investment and 2 other VCs)
10 Approval for Advanced Regenerative Clinical Study of Brain Tumor Therapeutic by the Ministry of Health and Welfare
09Selected for University-Industry Collaboration Platform Project: “Preclinical study of gene-modified MSCs using non-human primates”
09Selected for National New Drug Development Project: “Discovery of gene and cell therapy candidates for solid tumors”
2021
12 Series A financing secured (Pre-money valuation: KRW 18 billion, KRW 5 billion raised from Laguna Investment and 3 other VCs)
09 Selected for Regenerative Medicine R&D Program: “Preclinical study of CB-31, gene-modified MSCs for chronic stroke”
04 Venture Business Certification – Ministry of SMEs and Startups
03 Initiation of Investigator-Initiated Trial (IIT) for CB-11 (brain tumor cell therapy)
02 New share issued to Hanmi Pharm (Pre-money valuation: KRW 9.84 billion, KRW 160 million invested)
2020
12 Selected for BIG3 Promising Start-up Support Project: “Optimization of manufacturing process for gene-modified MSCs for brain diseases”
09Selected for Jeonbuk Techno Park Follow-up Advancement Project: “Production of gene-activated MSCs for brain activation”
05Selected for BIG3 Promising Start-up Support Project: “Safety evaluation assay for gene-modified stem cell therapy”
04 Selected for Advanced Medical Technology Development Project: “Platform and common technologies to enhance quality and competitiveness of cell therapies”
2019
12Patent transferred – Ajou University Industry-Academic Cooperation Foundation
10Pre-A financing secured (KRW 1.17 billion raised from N4U Holdings and 2 other investors)
08 Certified as an Affiliated Research Institute – Korea Industrial Technology Association
05 Selected for the Jeonbuk Special R&D Zone Technology Transfer and Commercialization Project: “Development of a performance evaluation model for gene-activated MSC therapy and definition of the target product profile”
2018
11Selected for Bio-Medical Technology Development Project: “Development of MSC-based therapy for chronic stroke”
